These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 579843)
1. [Morphological studies on proliferating breast changes under the influence of prolactin inhibiting drugs (proceedings)]. Zippel HH; Schulz KD; Del Pozo E Arch Gynakol; 1977 Jul; 224(1-4):338-9. PubMed ID: 579843 [No Abstract] [Full Text] [Related]
2. Combined anti-prolactin and anti-oestrogen therapy for breast carcinoma. Ward HW Clin Oncol; 1977 Mar; 3(1):91-5. PubMed ID: 862280 [No Abstract] [Full Text] [Related]
3. [Antiprolactin therapy in the treatment of benign lesions of the breast. Comparison of bromocryptine and methergoline]. Mussa A; Sandrucci S; Dogliotti L Minerva Med; 1979 Nov; 70(51):3493-8. PubMed ID: 522987 [TBL] [Abstract][Full Text] [Related]
4. [Bromocriptine in chemotherapy-resistant, metastatic breast cancer. Results of the GO-MC-BROMO 2/82 AIO Study]. Holtkamp W; Nagel GA Onkologie; 1988 Jun; 11(3):121-7. PubMed ID: 3045725 [TBL] [Abstract][Full Text] [Related]
6. A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines. Lissoni P; Bucovec R; Malugani F; Ardizzoia A; Villa S; Gardani GS; Vaghi M; Tancini G Anticancer Res; 2002; 22(2B):1131-4. PubMed ID: 12168912 [TBL] [Abstract][Full Text] [Related]
7. Failure of bromocriptine therapy to control juvenile mammary hypertrophy. Arscott GD; Craig HR; Gabay L Br J Plast Surg; 2001 Dec; 54(8):720-3. PubMed ID: 11728119 [TBL] [Abstract][Full Text] [Related]
8. [Role of prolactin in carcinogenesis and growth of mammary and breast neoplasms in animals and in man]. El'tsina NV Vopr Onkol; 1976; 22(12):81-91. PubMed ID: 798416 [TBL] [Abstract][Full Text] [Related]
9. Bromocriptine in the treatment of advanced breast cancer. Barrett A; Morgan L; Raggatt PR; Hobbs JR Clin Oncol; 1976 Dec; 2(4):373-7. PubMed ID: 1037393 [No Abstract] [Full Text] [Related]
10. [Possibilities and limitations of the treatment of secondary amenorrhea using the prolactin inhibitor 2-bromo-alpha-ergocryptine (proceedings)]. Tykal P; Brandl E; Schmolck A; Mettler L Arch Gynakol; 1977 Jul; 224(1-4):408-10. PubMed ID: 579878 [No Abstract] [Full Text] [Related]
11. Treatment of fibrocystic disease of the breast with a prolactin inhibitor: 2-Br-alpha-ergocryptine (CB-154). Martin-Comin J; Pujol-Amat P; Cararach V; Davi E; Robyn C Obstet Gynecol; 1976 Dec; 48(6):703-6. PubMed ID: 1036613 [TBL] [Abstract][Full Text] [Related]
16. Hyperprolactinemic amenorrhea in a woman with a craniopharyngioma: persisting amenorrhea after prolactin suppression with bromocriptine. Brandeis V; Kemmann E; Jones JR Am J Obstet Gynecol; 1983 Sep; 147(1):109-11. PubMed ID: 6614079 [No Abstract] [Full Text] [Related]
17. [Our experience in using bromocriptine-Richter in gynecology (a preliminary report)]. Marinov B; Tsankova M; Kolarov G Akush Ginekol (Sofiia); 2000; 39 Suppl 1():20-1. PubMed ID: 10948639 [No Abstract] [Full Text] [Related]
18. [Effect of parlodel and thyroliberin on prolactin secretion in patients with fibrocystic mastopathy]. Sturia NT Probl Endokrinol (Mosk); 1983; 29(2):21-4. PubMed ID: 6406998 [TBL] [Abstract][Full Text] [Related]
19. [Remote results of treatment of galactorrhea-amenorrhea syndromes and functional sterility with increased prolactin concentration by means of bromocriptine (Parlodel-Sandoz)]. Tomala J; Dudkiewicz J; Blecharz AJ Ginekol Pol; 1980 Mar; 51(3):255-8. PubMed ID: 6771191 [No Abstract] [Full Text] [Related]
20. Caution in the use of bromocriptine in peripartum cardiomyopathy. Fett JD J Am Coll Cardiol; 2008 May; 51(21):2083; author reply 2083-4. PubMed ID: 18498970 [No Abstract] [Full Text] [Related] [Next] [New Search]